Related Experiment Video
Updated: Mar 11, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.7K
[Lipid-lowering drugs and PCSK9]
Jesús Millán Núñez-Cortés1, José M Mostaza Prieto2
1Unidad de Lípidos y Riesgo Vascular, Hospital General Universitario Gregorio Marañón, Madrid, España.
Summary
This review examines how lipid-lowering drugs affect PCSK9. Statins and ezetimibe increase PCSK9, while fibrates and niacin may decrease it, impacting LDL receptor levels.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Medicine
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of LDL receptor metabolism.
- PCSK9 promotes hepatic degradation of LDL receptors, reducing LDL cholesterol clearance.
- Statins reduce cholesterol synthesis, upregulating LDL receptor expression and consequently PCSK9 levels.
Purpose of the Study:
- To review the impact of various lipid-lowering drugs on plasma PCSK9 concentrations.
- To understand the interplay between lipid-lowering therapies and PCSK9 regulation.
- To provide insights into therapeutic strategies targeting PCSK9.
Main Methods:
- Literature review of studies investigating lipid-lowering drugs and PCSK9 levels.
- Analysis of the mechanisms by which different drug classes influence PCSK9.
- Synthesis of findings on PCSK9 modulation by statins, ezetimibe, fibrates, and niacin.
Main Results:
- Statins consistently increase serum PCSK9 concentrations.
- Ezetimibe enhances the statin-induced increase in PCSK9.
- Fibrates and niacin may lead to a decrease in PCSK9 levels.
Conclusions:
- Different classes of lipid-lowering drugs exert varied effects on PCSK9.
- Understanding these effects is crucial for optimizing lipid management and cardiovascular risk reduction.
- PCSK9 modulation by these drugs offers potential therapeutic targets.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:29Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
01:26Atherosclerosis III: Management
541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
01:26Coronary Artery Disease IV: Preventive Measures
790
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790
01:27Coronary Artery Disease V: Interprofessional Care
357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
01:27Peripheral Artery Disease III: Interprofessional Care
486
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
486